INTERLEUKIN LEVELS IN THE PATHOGENESIS OF CORONAVIRUS  INFECTION (COVID-19) AND THE EFFECT OF A NEW COMBINATION DRUG (G.  LUCIDUM AND ALKHADAYA) ON THE COURSE AND PROGNOSIS OF THE  DISEASE

dc.contributor.author	Abilov P.M., Makhkamova F.T.
dc.date.accessioned	2026-04-20T09:59:35Z
dc.date.available	2026-04-20T09:59:35Z
dc.date.issued	2025
dc.identifier.uri	http://repo.tma.uz/xmlui/handle/1/3734
dc.description.abstract	An outbreak of acute community acquired atypical pneumonia of unknown etiology was reported in Wuhan, the capital of Hubei Province in central China, in December 2019. The pathogen, which turned out to be a new coronavirus, had not previously been detected in human papillomaviruses and was named SARS CoV-2. On March 11, 2020, the WHO recognized the NCI epidemic as a pandemic. SARS-CoV-2 belongs to the genus Betacoronavirus family Coronaviridae .	en_US
dc.language.iso	en_US	en_US
dc.publisher	O'zbekiston, Toshkent ( Stomatologiya ) jurnal	en_US
dc.relation.ispartofseries	UDC;616.994.41-006.6-018.1:616.19-002
dc.title	INTERLEUKIN LEVELS IN THE PATHOGENESIS OF CORONAVIRUS INFECTION (COVID-19) AND THE EFFECT OF A NEW COMBINATION DRUG (G. LUCIDUM AND ALKHADAYA) ON THE COURSE AND PROGNOSIS OF THE DISEASE	en_US
dc.type	Article	en_US